Background: Health-related quality of life (HRQoL) assessment on female with urinary incontinence (UI) may be a useful indicator in the management of early treatment depending on the sort of UI which is dominant: Stress UI or Urge UI. The objective of the present study was to evaluate the HRQoL of female with mixed UI, comparing the impact of symptoms of Urge UI and Stress UI.
Patients And Methods: This is an epidemiologic, cross-sectional and multicenter study. HRQoL of 1,100 women with mixed UI was evaluated using the Spanish version of "King's Health Questionnaire" (KHQ). Personal data of patients were also collected along with medical records and clinical data related to diagnostic and treatment of UI.
Results: Urinary infection was the most frequent medical record found. Mean time since start of UI symptoms was 4 years and 44% of patients had been received some treatment for UI. It was observed a higher use of sanitary napkins (63.9%) than pantyliners (36%) and diapers (11.2%). Mean global score of the KHQ was 42.2 (S.D.= 18.7); higher impact on HRQoL was shown in dimensions: UI impact, Urinary problems and Physical Limitations. Urge UI symptoms cause higher impact on HRQoL than Stress UI symptoms (p< 0.0001). The logistic regression model performed for global KHQ score showed that variables strongly associated were Urge UI, genital prolapse and coital UI symptom.
Conclusions: Women with mixed UI showed and important impact on HRQoL. This impact is strongly associated with presence of symptoms of Urge UI.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0210-4806(09)74167-1 | DOI Listing |
Alzheimer's disease pathophysiology is believed to involve various abnormalities, including those of amyloid beta (Ab) peptide and tau processing, inflammation, oxidative stress, and vascular risk factors. Aβ peptides exist in a dynamic continuum of conformational states from monomeric Aβ, to soluble progressively larger Aβ assemblies that include a range of low molecular weight oligomers to higher molecular weight protofibrils, and finally to insoluble fibrils (plaques). Various lines of evidence support the "amyloid hypothesis" that Aβ plays a central role in the pathogenesis of AD, and several immunotherapies have been developed to interact with this cascade in various different places which may reduce the number of soluble aggregates and insoluble Aβ fibrils deposited in the brain.
View Article and Find Full Text PDFBackground: Lecanemab is an approved anti-amyloid monoclonal antibody that binds with highest affinity to soluble Aβ protofibrils, which are more toxic than monomers or insoluble fibrils/plaque. In clinical studies, biweekly lecanemab treatment demonstrated a slowing of decline in clinical (global, cognitive, functional, and quality of life) outcomes, and reduction in brain amyloid in early Alzheimer's disease (AD). Herein, we describe the impact of lecanemab treatment on tau PET.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
ivision of Cognitive Neuroscience, John's Hopkins University School of Medicine, Baltimore, MD, USA.
Background: People living with dementia (PwD) experience progressive functional decline with increasing dependence on their caregivers. Advanced care planning (ACP) has the potential to promote quality of life, reduce iatrogenic harm, and minimize overutilization of healthcare resources, yet planning ahead in the context of dementia is challenging and requires consideration of numerous factors over an extended period of time. We examined caregivers' perceptions of current and end-stage medical care preferences in PwD and the impact of ACP-related discussions between caregivers and PwD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
College of Public Health, University of Kentucky, Lexington, KY, USA.
Background: Behavioral and psychological symptoms of people living with dementia (BPSD) are considered to reflect the person's quality of life and are also risk factors for increased burden on caregivers. Although symptoms of BPSD are known to be diverse and variable, it is unclear whether they show similar longitudinal patterns in different countries. Therefore, this study aimed to clarify the trajectory patterns in BPSD and related factors using data from Japan and the US and compare the results of the two countries.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
RWJ Barnabas Health, West Orange, NJ, USA.
Background: Effect and Safety of Electroconvulsive Therapy plus Usual Care for the Acute Management of Severe Agitation in Dementia (ECT-AD) is a multi-site NIA-funded FDA-regulated pioneering clinical trial to investigate the effectiveness of electroconvulsive therapy (ECT) in treating severe and treatment-refractory agitation and aggression among individuals with advanced dementia, a condition that has a profound negative impact on patient quality of life and caregiver burden. Here we present baseline demographics of the patient population in this ongoing trial.
Method: To date we have enrolled 18 participants, with a mean age of 74.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!